Yadong Wang

Oct 4, 2024 | bmcgenomics.biomedcentral.com | Shichen Gao |Yadong Wang |Jiajia Wang |Yan Dong

The analysis of single-cell transcriptomic data can markedly enhance our understanding of the pathogenic mechanisms underlying HD. Therefore, we used recently accessible single-cell RNA sequencing data [11], which includes two datasets derived from induced pluripotent stem cells (iPSCs) of (i) unaffected control individuals and (ii) HD patients (Fig. 2, left panel). These iPSCs were differentiated into neuron cultures enriched with medium spiny neurons, the cell type predominantly impacted in HD.

Jul 2, 2024 | mdpi.com | Yadong Wang |Chong Liu

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 6, 2024 | nature.com | Yadong Wang

AbstractImmune-related GTPase M (IRGM) induces autophagy and suppresses inflammation, but its putative role and signaling mechanism remain undefined in the pathogenesis of liver failure. This study aimed to address how IRGM attenuates inflammatory injury by regulating autophagy in liver failure. In this study, a total of 10 patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) and 10 healthy controls were prospectively enrolled.

Apr 22, 2024 | nature.com | Yadong Wang

AbstractLung adenocarcinoma is a malignant tumor with high morbidity and mortality. ZBTB16 plays a double role in various tumors; however, the potential mechanism of ZBTB16 in the pathophysiology of lung adenocarcinoma has yet to be elucidated. We herein observed a decreased expression of ZBTB16 mRNA and protein in lung adenocarcinoma and a significantly increased DNA methylation level of ZBTB16 in patients with lung adenocarcinoma.

Aug 18, 2023 | nature.com | Yadong Wang |Guanghui Wang

AbstractOsimertinib is a promising approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for treating patients with lung adenocarcinoma (LUAD) harboring EGFR-activating mutations, however, almost all patients develop resistance to Osimertinib eventually limiting the long-term efficacy. Autophagy is a vital cellular recycling process promoting Osimertinib resistance.